Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Platinum-resistant ovarian cancer, drawn from the whole corpus: 40 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Sequencing antibody-drug conjugates that share topoisomerase or tubulin payloads.
Whether platinum resistance can be reversed rather than bypassed.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
A definition of resistance based on biology rather than a six-month clock.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
OS 18.
ORR 55.
OS 16.
A milestone in how this cancer is treated.